Integrating tools for breast cancer risk assessment, risk reduction, and early detection

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 10, 2010, Pages 2428-2429

  Ward, Elizabeth M ^a   Smith, Robert A ^a  

^a AMERICAN CANCER SOCIETY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; RALOXIFENE; TAMOXIFEN;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; FAMILY HISTORY; GENE MUTATION; GENETIC COUNSELING; HUMAN; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MASTECTOMY; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARIECTOMY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; UNITED STATES;

BREAST NEOPLASMS; FEMALE; HUMANS; RISK ASSESSMENT; RISK FACTORS;

EID: 77958057198     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0835     Document Type: Note

References (16)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010. Epub 2010 Jul 7.
2. Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 2003;53:141-69.
3. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2009;151:727-37, W237-42.
4. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:75-89. (Pubitemid 46535708)
5. Bevers TB, Anderson BO, Bonaccio E, et al. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. Fort Washington, PA: National Comprehensive Cancer Network; 2010.
6. Visvanathan K, Chlebowski RT, Hurley P, et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009;27:3235-58.
7. Hall IJ, Burke W, Coughlin S, Lee NC. Population-based estimates of the prevalence of family history of cancer among women. Community Genet 2001;4:134-42. (Pubitemid 34293646)
8. Samphao S, Wheeler AJ, Rafferty E, et al. Diagnosis of breast cancer in women age 40 and younger: delays in diagnosis result from underuse of genetic testing and breast imaging. Am J Surg 2009;198:538-43.
9. Guerra CE, Sherman M, Armstrong K. Diffusion of breast cancer risk assessment in primary care. J Am Board Fam Med 2009;22:272-9.
10. Gross CP, Filardo G, Singh HS, Freedman AN, Farrell MH. The relation between projected breast cancer risk, perceived cancer risk, and mammography use. Results from the National Health Interview Survey. J Gen Intern Med 2006;21:158-64. (Pubitemid 43363672)
11. Waters EA, Cronin KA, Graubard BI, Han PK, Freedman AN. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev 2010;19:443-6.
12. Armstrong K, Micco E, Carney A, Stopfer J, Putt M. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA 2005;293:1729-36. (Pubitemid 40491298)
13. Hall MJ, Olopade OI. Disparities in genetic testing: thinking outside the BRCA box. J Clin Oncol 2006;24:2197-203.
14. Kerlikowske K, Cook AJ, Buist DS, et al. Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use. J Clin Oncol 2010;28:3830-7.
15. Murphy CD, Lee JM, Drohan B, et al. The American Cancer Society guidelines for breast screening with magnetic resonance imaging: an argument for genetic testing. Cancer 2008;113:3116-20.
16. Dominguez FJ, Jones JL, Zabicki K, et al. Prevalence of hereditary breast/ovarian carcinoma risk in patients with a personal history of breast or ovarian carcinoma in a mammography population. Cancer 2005;104:1849-53.